Clinuvel receives IND status
Thursday, 29 January, 2009
Melbourne’s Clinuvel has received investigational new drug (IND) status for its photoprotective drug afamelanotide from the US FDA.
The ruling will allow the company to begin clinical trials in the US. It received orphan drug designation from the FDA in July last year.
Afamelanotide is currently in Phase III trials for the treatment of erythropoietic protoporphyria (EPP) in Europe and Australia, amongst several other trials in UV-related skin disorders.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
